IIT Bhubaneswar Signs Agreement for TB Vaccine
Bhubaneswar: In a significant development for tuberculosis (TB) vaccine research, IIT Bhubaneswar has entered into a Quadripartite License Agreement with the Institute of Life Sciences (ILS), the National Research Development Corporation (NRDC), and TechInvention Lifecare Limited. This agreement marks a pivotal step towards advancing the technology transfer and potential commercialization of a promising new vaccine candidate known as the “HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis.”
Background on Tuberculosis
According to the World Health Organization (WHO), tuberculosis remains one of the deadliest infectious diseases globally. In 2024, TB claimed approximately 1.23 million lives, highlighting the urgent need for effective vaccines and treatments. Despite the availability of the Bacillus Calmette Guérin (BCG) vaccine, which was developed over a century ago, its effectiveness is limited. The BCG vaccine primarily protects infants and is largely ineffective in preventing pulmonary TB in adolescents and adults.
The Need for a New Vaccine
The limitations of the BCG vaccine have created a critical unmet need for a next-generation vaccine that can provide broader and more effective protection against TB. The newly developed HSP Subunit Vaccine aims to address these gaps by eliciting strong humoral and cell-mediated immune responses, thereby enhancing the protective efficacy of the existing BCG vaccine.
Collaboration and Development
The HSP Subunit Vaccine has been developed through collaborative research led by:
- Prof. Ashis Biswas from IIT Bhubaneswar
- Dr. Sunil Kumar Raghav from the Institute of Life Sciences (ILS), Bhubaneswar
This collaboration exemplifies the strength of India’s research ecosystem and its commitment to addressing significant public health challenges. The NRDC has played a proactive role in identifying and evaluating this innovative technology, facilitating the licensing process to ensure the advancement of the vaccine candidate.
Commercialization and Future Prospects
TechInvention Lifecare Limited, the licensed industry partner, will be instrumental in translating this indigenous vaccine technology into a viable public health solution. The agreement aims to transition the vaccine from laboratory research to product development and eventual commercial deployment, which is crucial for improving TB prevention strategies in India and around the world.
Significance of the Agreement
This agreement is not just a milestone for the institutions involved but also represents a broader effort to enhance public health in India. The HSP Subunit Vaccine is expected to play a significant role in combating Mycobacterium tuberculosis, which is responsible for the majority of TB cases worldwide. The collaboration between IIT Bhubaneswar, ILS, NRDC, and TechInvention Lifecare Limited underscores the importance of partnerships in advancing health technologies and addressing global health issues.
Conclusion
The signing of this agreement is a promising development in the fight against tuberculosis. With the potential to improve vaccine efficacy and broaden protection against TB, the HSP Subunit Vaccine could significantly impact public health. As the world continues to grapple with the challenges posed by infectious diseases, innovations like this are critical in paving the way for a healthier future.
Note: The information provided in this article is based on the latest updates and research available as of November 2025.
